Cantor Fitzgerald raised the firm’s price target on Harrow (HROW) to $94 from $76 and keeps an Overweight rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow Health: Strong Product Performance and Strategic Moves Justify Buy Rating
- Closing Bell Movers: CoreWeave down over 5% on lower sales, higher capex view
- Harrow Health Reports Strong Q3 2025 Financial Results
- Harrow reports Q3 core EPS 33c, consensus 29c
- HROW Earnings this Week: How Will it Perform?